Q3 EPS Estimates for Zimmer Biomet Boosted by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Equities research analysts at Zacks Research increased their Q3 2026 earnings per share (EPS) estimates for Zimmer Biomet in a research report issued to clients and investors on Monday, June 16th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will earn $2.02 per share for the quarter, up from their prior forecast of $2.00. The consensus estimate for Zimmer Biomet's current full-year earnings is $8.22 per share.

A number of other research analysts have also recently weighed in on ZBH. Canaccord Genuity Group dropped their price objective on shares of Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating for the company in a research note on Monday, May 12th. JPMorgan Chase & Co. decreased their price target on shares of Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. Raymond James Financial decreased their price target on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Truist Financial set a $101.00 price target on shares of Zimmer Biomet in a report on Tuesday, May 6th. Finally, Robert W. Baird lowered their target price on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $111.53.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH traded up $0.67 during mid-day trading on Thursday, hitting $91.22. 4,060,771 shares of the company were exchanged, compared to its average volume of 1,795,968. The firm has a market cap of $18.05 billion, a price-to-earnings ratio of 20.18, a price-to-earnings-growth ratio of 2.11 and a beta of 0.72. The stock has a 50 day simple moving average of $95.28 and a 200-day simple moving average of $102.80. Zimmer Biomet has a 1-year low of $89.22 and a 1-year high of $116.71. The company has a quick ratio of 1.46, a current ratio of 2.44 and a debt-to-equity ratio of 0.53.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The company had revenue of $1.91 billion for the quarter, compared to analysts' expectations of $1.89 billion. During the same period in the prior year, the firm earned $1.94 earnings per share. The firm's revenue was up 1.1% compared to the same quarter last year.

Institutional Trading of Zimmer Biomet

A number of large investors have recently added to or reduced their stakes in ZBH. Garde Capital Inc. bought a new stake in Zimmer Biomet during the first quarter valued at $29,000. Washington Trust Advisors Inc. purchased a new stake in Zimmer Biomet in the first quarter worth $30,000. Columbia River Financial Group LLC bought a new stake in shares of Zimmer Biomet during the first quarter valued at approximately $30,000. Menard Financial Group LLC purchased a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $30,000. Finally, Accent Capital Management LLC bought a new position in shares of Zimmer Biomet during the first quarter valued at $35,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Insider Transactions at Zimmer Biomet

In related news, insider Sang Yi sold 1,000 shares of Zimmer Biomet stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the sale, the insider now owns 20,424 shares of the company's stock, valued at approximately $1,940,280. This trade represents a 4.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 1.39% of the company's stock.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.05%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's payout ratio is 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.